Hong Kong-based venture capital group ORI Healthcare Fund has announced investment of $18 million into Pillar Biosciences, a Boston-based cancer research firm.
Pillar Biosciences is developing technologies and products for cancer diagnostics driven by next-generation sequencing (NGS). ORI Fund is a $200 million venture capital fund focused on investing in the healthcare industry globally. The fund is founded by Ms. Simone Hong Fang Song, former investment banker and head of China Healthcare at Goldman Sachs.
To see a list of investors from China similar to ORI Healthcare Fund, check the Chinese Investors Directory.
More details follows:
Previous Post: Chinese investors acquired the 134-year-old Chicago Stock Exchange
Next Post: Chinese investors acquired US printer manufacturer Lexmark for $3.6 billion